Synhale Therapeutics

Executive Summary

Synhale Therapeutics is a preclinical-stage biotechnology company based in Cambridge, MA, focused on developing novel inhaled therapeutics for respiratory and pulmonary diseases. Founded in 2020, the company has raised $75 million to advance its proprietary inhalation platform, which aims to improve drug delivery to the lungs while minimizing systemic side effects. The company's lead programs target chronic respiratory conditions such as asthma, COPD, and pulmonary fibrosis, leveraging its expertise in formulation and device engineering. With a strong financial base and a rapidly growing team of 50–200 employees, Synhale is positioned to transition from preclinical development to IND-enabling studies within the next 12–18 months. Its innovative approach addresses significant unmet needs in respiratory medicine, including the challenges of drug deposition, lung retention, and patient adherence. While still in early stages, the company's robust funding and focus on high-value indications suggest potential for significant clinical and commercial impact.

Upcoming Catalysts (preview)

• Q3 2026IND filing for lead inhaled program (e.g., SYN-101 for asthma/COPD)70% success
• Q2 2026Preclinical efficacy data readout in pulmonary fibrosis model80% success
• Q4 2026Partnership or licensing deal for inhalation platform technology50% success